In this study, the observation of TrxR1 overexpression in clinical CD34+ AML samples sheds new light on the possibility of treating AML (especially relapsed AML) patients with TrxR1 inhibitors. This evidence concerns the gene TXNRD1 and acute myeloid leukemia.